Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Well, HOW "fine" are ya doin', Bro??? If ya tossed circa $10K (USD) at it at the "dip", ya might have $2K profit --- right??? CONGRATS!!! (That's what I do, too!!)
I’m doing fine on it. Trade ‘em
NOT a "good catch", Sir! In truth, a classic SUCKERS' BATE MORNING GAPPER! (Unless you owned a ton of this the proverbial YESTERDAY.)
They're going to need to address the SP soon before they get delisted from major exchange.
Bought on the 42.77% price drop - let's see where it goes from here.
In at .2675
thanks for posting this, i waited for some time to buy it at .40 cents
Just 3000 shares
I'll see what the morning brings
they haven't updated their SS since 11/05/21
so they maybe diluting and shorts pushing with big asks
guess I'll be leaving in the morning sun if that's the case
great post by the way
Coverage of ALNA on Frugalnorwegian.com
https://frugalnorwegian.com/alna
All the best.
Sure was alot of new bag holders made premarket on this one.in after they pulled the rug out .on this
Low floater, but still in FDA phase II trials.
ALNA
Allena Pharmaceuticals Gets Fast Track Designation for Kidney Disease Treatment
8:15 am ET November 3, 2021 (Dow Jones) Print
By Chris Wack
Allena Pharmaceuticals Inc. said its orally-administered, urate-degrading enzyme, ALLN-346, has received Fast Track designation from the U.S. Food and Drug Administration.
ALLN-346 is in Phase 2 development for the treatment of hyperuricemia in gout patients with advanced chronic kidney disease.
The biopharmaceutical company said that in gout patients with advanced CKD, the intestinal tract becomes the primary route of elimination for urate, and ALLN-346 is specifically designed to capitalize on this physiologic adaptation by enhancing the breakdown and secretion of urate in the intestinal tract.
The Phase 2a program is comprised of a one-week inpatient trial and a two-week outpatient trial, designed to assess initial bioactivity data and additional safety data for ALLN-346.
Allena plans to report initial data from these studies in late 2021 or early 2022. Initial data from the Phase 2a program will potentially assist the company in determining the optimal dosing paradigm and target population for later stage clinical trials.
Allena shares were up 11% to 95 cents in premarket trading.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
Just saw this. Thank you!
Shares Outstanding 80.1 million. This has gone up quite a bit. Just posting this here so we can see if it gets higher in the coming months/years.
FN, thank you, see you there :)
$ALNA yyyuuuuuppp!!
https://stocktwits.com/Mygolfballs/message/359113260
New community for additional DD on ALNA:
https://www.reddit.com/r/ALNA_Stock/
Why is this still .50 cent lower than offering?
Clowns
Wait
3 day rule here imo
I grabbed a little. -33% is huge. Should see some upside in a month or two.
Tutorial: How to get delisted from major exchange.
Taking a break from trading this. I believe we are in a new trading range and it can drop suddenly leaving you stuck in an unfavorable position. Good luck!
Back at $1.35. Patience, only took two months. Good time to start a position but buy small, it's going lower! Just my opinion.
Do not buy above $1.40! it will bounce at $1.31, $1.26, and $1.22. Put your orders in at these levels. Just my opinion. Good luck guys! patience paid off!
Retesting critical support line. It will break through and fall further. Be patient! And then we can load the boat.
Double top bearish. Be patient, downward pressure back under $1.40 over the next few months. The hype should die down, no news ahead.
Next upcoming catalyst
Reloxaliase: Reloxaliase is a first-in-class, non-absorbed, orally administered enzyme for the treatment of severe hyperoxaluria. Allena is currently evaluating reloxaliase for patients with enteric hyperoxaluria (EH) in URIROX-2, the second pivotal Phase 3 clinical trial in its URIROX program. Allena is actively expanding to new sites and new geographies in its ongoing URIROX-2 clinical trial. The Company continues to expect the interim analysis in the first quarter of 2022 and to announce topline data supporting a potential Biologics License Application (BLA) submission in the third quarter of 2022.
* * $ALNA Video Chart 01-26-2021 * *
Link to Video - click here to watch the technical chart video
This bump up to over $1.60 is the highest since October of last year. Holding my long position for now. I stopped trading at the moment, patiently waiting for $1.20's again.
After the close on Friday: RGLS and ALNA
Steven Cohen Boosts Health Care Exposure With 2 Biotech Stocks
GuruFocus.com
Fri, December 11, 2020, 5:27 PM EST
https://finance.yahoo.com/news/steven-cohen-boosts-health-care-222701075.html
"Billionaire investor Steven Cohen (Trades, Portfolio) disclosed earlier this week his firm, Point72 Asset Management, established a 14.37% stake in Regulus Therapeutics Inc. (NASDAQ:RGLS) and a 7.96% position in Allena Pharmaceuticals Inc. (NASDAQ:ALNA) on Dec. 4. ..."
Still waiting we could see $1.22 this week.
Be patient...Wait for the dip
Followers
|
14
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
145
|
Created
|
11/19/19
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |